Studies

Studies have found that Preimplantation Genetic Diagnosis (PGD) significantly raises the success of live-birth rates by screening for chromosomal abnormalities in women who have recurrent pregnancy loss (RPL), and advanced maternal age (AMA). These studies have also shown that there is no significant affect on women with repeated failed IVF cycles (FC). The following are studies that support the use of PGD for fertility treatment.

PREIMPLANTATION GENETIC DIAGNOSIS (PGD) AS BOTH A DIAGNOSTIC AND THERAPEUTIC TOOL IN ASSISTED REPRODUCTIVE TECHNOLOGY

PHASE 1

Summary:
Women who suffer from recurrent pregnancy loss (RPL) may be interested to know that a study on Preimplantation Genetic Diagnosis (PGD) confirms that aneuploidy, an abnormal number of chromosomes that can lead to a chromosomal disorder, is a common cause.
Objective: To evaluate the role of PGD as both a diagnostic and therapeutic tool in ART.
Design: An IRB approved, multicenter, randomized prospective study was initiated with 60 patients. Three high-risk groups were identified: 1. Group I: Women with recurrent pregnancy loss(RPL); 2. Group II: Women with advanced maternal age (AMA); 3. Group III: Women who have failed >2 IVF cycles (FC)

Conclusion:
1.) PGD confirms that Aneuploidy is a common cause of RPL
2.) PGD appears to be beneficial in the RPL group
3.) It is not clear as yet whether PGD is beneficial in the AMA group
4.) PGD offers no benefit to the FC group
5.) In the view of the large number of abnormal embryos in each group, couples may consider alternative options earlier, such as donor oocytes, donor embryos and/or adoption
»View the Study Poster

PREIMPLANTATION GENETIC DIAGNOSIS (PGD) AS A BENEFICIAL TOOL IN WOMEN WITH RECURRENT PREGNANCY LOSS (RPL) AND ADVANCED MATERNAL AGE (AMA)

PHASE 2

Summary:
Preimplantation Genetic Diagnosis (PGD) is recommended for patients with recurring pregnancy loss and/or advanced maternal age to screen for abnormal embryos. PGD increases the likelihood of a successful pregnancy by diagnosing chromosomal abnormalities and allowing for healthy embryos to be implanted.
Objective: Previously, we reported data from the first IRB approved, randomized, prospective study looking at patients who are at higher risk for aneuploidic embryos. It was demonstrated that PGD may be beneficial in the RPL group, but it was not clear whether PGD would be beneficial in
the AMA group. In an effort to determine if PGD is beneficial in both groups, the study was expanded.
Design: A randomized, prospective, IRB approved study.

Conclusion:
1.) It was reconfirmed that in patients with RPL, PGD is beneficial.
2.) It now appears that PGD may also be beneficial in the AMA group.
3.) In view of the large number of abnormal embryos in both groups, couples may consider
alternative options earlier, such as donor oocytes, donor embryos, and/or adoption.
»View the Study Poster

ARE SPECIFIC TYPES OF ANEUPLOIDY MORE COMMON IN HIGH-RISK PATIENTS UNDERGOING PREIMPLANTATION GENETIC DIAGNOSIS (PGD)

Summary:
The study shows that women with recurrent pregnancy loss (RPL), advanced maternal age (AMA) and repeated failed IVF cycles (FC) are 65.4% likely to have aneuploidic embryos and may benefit from Preimplantation Genetic Diagnosis (PGD), which screens for abnormal chromosomes.
Objective: Cytogenetic analyses have shown that more than half of all preimplantation embryos contain aneuploidic cells. We have previously published data demonstrating that three groups of patients are at higher risk for aneuploidic embryos. 1.) Patients with recurrent pregnancy loss (RPL); 2.) Patients with advanced maternal age (AMA); 3.) Patients with repeated failed IVF cycles (FC). In an effort to determine if specific types of aneuploidies are more common in these high-risk groups, we retrospectively reviewed karyotypes of 188 embryos biopsied from 40 patients who had been prospectively randomized to undergo PGD from a total of 87 patients enrolled from Aug1, 2001 – Dec 1, 2003.
Design: A retrospective analysis

Conclusion:
1.) Of the embryos biopsied in these high-risk patients, 65.4% were aneuploidic.
2.) Of these aneuploidic embryos, almost 40% were complexly abnormal.
3.) Of these aneuploidic embryos 25.2% (31/123) had only one chromosome affected.
Thus 74.8% (92/123) had two or more chromosomes affected.
4.) In view of the large number of aneuploidic embryos in these high risk groups, PGD
should be considered as a therapeutic tool to either improve outcome or assist
patients in considering other alternatives.

http://genesisivf.com/studies.htm
Studies have found that Preimplantation Genetic Diagnosis (PGD) significantly raises the success of live-birth rates by screening for chromosomal abnormalities in women who have recurrent pregnancy loss (RPL), and advanced maternal age (AMA). These studies have also shown that there is no significant affect on women with repeated failed IVF cycles (FC). The following are studies that support the use of PGD for fertility treatment.

PREIMPLANTATION GENETIC DIAGNOSIS (PGD) AS BOTH A DIAGNOSTIC AND THERAPEUTIC TOOL IN ASSISTED REPRODUCTIVE TECHNOLOGY

PHASE 1

Summary:
Women who suffer from recurrent pregnancy loss (RPL) may be interested to know that a study on Preimplantation Genetic Diagnosis (PGD) confirms that aneuploidy, an abnormal number of chromosomes that can lead to a chromosomal disorder, is a common cause.
Objective: To evaluate the role of PGD as both a diagnostic and therapeutic tool in ART.
Design: An IRB approved, multicenter, randomized prospective study was initiated with 60 patients. Three high-risk groups were identified: 1. Group I: Women with recurrent pregnancy loss(RPL); 2. Group II: Women with advanced maternal age (AMA); 3. Group III: Women who have failed >2 IVF cycles (FC)

Conclusion:
1.) PGD confirms that Aneuploidy is a common cause of RPL
2.) PGD appears to be beneficial in the RPL group
3.) It is not clear as yet whether PGD is beneficial in the AMA group
4.) PGD offers no benefit to the FC group
5.) In the view of the large number of abnormal embryos in each group, couples may consider alternative options earlier, such as donor oocytes, donor embryos and/or adoption
»View the Study Poster

PREIMPLANTATION GENETIC DIAGNOSIS (PGD) AS A BENEFICIAL TOOL IN WOMEN WITH RECURRENT PREGNANCY LOSS (RPL) AND ADVANCED MATERNAL AGE (AMA)

PHASE 2

Summary:
Preimplantation Genetic Diagnosis (PGD) is recommended for patients with recurring pregnancy loss and/or advanced maternal age to screen for abnormal embryos. PGD increases the likelihood of a successful pregnancy by diagnosing chromosomal abnormalities and allowing for healthy embryos to be implanted.
Objective: Previously, we reported data from the first IRB approved, randomized, prospective study looking at patients who are at higher risk for aneuploidic embryos. It was demonstrated that PGD may be beneficial in the RPL group, but it was not clear whether PGD would be beneficial in
the AMA group. In an effort to determine if PGD is beneficial in both groups, the study was expanded.
Design: A randomized, prospective, IRB approved study.

Conclusion:
1.) It was reconfirmed that in patients with RPL, PGD is beneficial.
2.) It now appears that PGD may also be beneficial in the AMA group.
3.) In view of the large number of abnormal embryos in both groups, couples may consider
alternative options earlier, such as donor oocytes, donor embryos, and/or adoption.
»View the Study Poster

ARE SPECIFIC TYPES OF ANEUPLOIDY MORE COMMON IN HIGH-RISK PATIENTS UNDERGOING PREIMPLANTATION GENETIC DIAGNOSIS (PGD)

Summary:
The study shows that women with recurrent pregnancy loss (RPL), advanced maternal age (AMA) and repeated failed IVF cycles (FC) are 65.4% likely to have aneuploidic embryos and may benefit from Preimplantation Genetic Diagnosis (PGD), which screens for abnormal chromosomes.
Objective: Cytogenetic analyses have shown that more than half of all preimplantation embryos contain aneuploidic cells. We have previously published data demonstrating that three groups of patients are at higher risk for aneuploidic embryos. 1.) Patients with recurrent pregnancy loss (RPL); 2.) Patients with advanced maternal age (AMA); 3.) Patients with repeated failed IVF cycles (FC). In an effort to determine if specific types of aneuploidies are more common in these high-risk groups, we retrospectively reviewed karyotypes of 188 embryos biopsied from 40 patients who had been prospectively randomized to undergo PGD from a total of 87 patients enrolled from Aug1, 2001 – Dec 1, 2003.
Design: A retrospective analysis

Conclusion:
1.) Of the embryos biopsied in these high-risk patients, 65.4% were aneuploidic.
2.) Of these aneuploidic embryos, almost 40% were complexly abnormal.
3.) Of these aneuploidic embryos 25.2% (31/123) had only one chromosome affected.
Thus 74.8% (92/123) had two or more chromosomes affected.
4.) In view of the large number of aneuploidic embryos in these high risk groups, PGD
should be considered as a therapeutic tool to either improve outcome or assist
patients in considering other alternatives.